
About Artiva:
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases. We aim to develop therapies that patients and physicians can utilize in a community setting. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). We believe the compelling cell killing properties of NK cells, when combined with mAbs for targeting, creates an opportunity to generate potentially transformative therapies.
For more information, visit www.artivabio.com.
Artiva Biotherapeutics is seeking a skilled and highly motivated Senior Scientist I/II who will be responsible for translational assay oversight and data analysis in support of ongoing clinical trials. This position will work with senior translational leadership to identify pharmacodynamic and predictive biomarkers associated with NK cell-mediated clinical response. The ideal candidate brings prior translational science experience supporting clinical trials, a strong background in immunology (B-cell immunology preferred), and hands-on expertise in flow cytometry analysis. The successful candidate will contribute to biomarker development and analysis to support ongoing clinical trials in autoimmunity.
Competencies:
In addition to a great culture, we offer:
If all this speaks to you, come join us on our journey!
Base Salary: $149,000 - 183,000 annually. Exact compensation may vary based on level, skills and experience.

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.